Pacific Biosciences Of California (PACB) Equity Average (2011 - 2026)

Pacific Biosciences Of California has reported Equity Average for 16 years, with the latest figure at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 98.71% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.9 million (down 98.71% YoY), and the FY2025 full-year result was $256.0 million, down 57.62% from the prior year.
• Equity Average for Q1 2026 stood at $3.9 million, down from $20.7 million in the prior quarter.
• The five-year high for Equity Average was $762.8 million in Q1 2022, with the low at $3.9 million in Q1 2026.
• Average Equity Average over 5 years is $476.3 million, with a median of $594.7 million recorded in 2022.
• Year-over-year, Equity Average soared 162.89% in 2022 and plunged 98.71% in 2026.
• Tracing PACB's Equity Average over 5 years: stood at $594.7 million in 2022, then climbed by 23.17% to $732.5 million in 2023, then sank by 34.49% to $479.9 million in 2024, then sank by 95.68% to $20.7 million in 2025, then tumbled by 81.38% to $3.9 million in 2026.
• The last three Equity Average figures came in at $3.9 million (Q1 2026), $20.7 million (Q4 2025), and $48.8 million (Q3 2025), per Business Quant data.

Peer Comparison